Janus Henderson Group PLC Purchases 25,089 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Janus Henderson Group PLC boosted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 56.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,207 shares of the company’s stock after acquiring an additional 25,089 shares during the quarter. Janus Henderson Group PLC’s holdings in Medpace were worth $23,002,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MEDP. Lindbrook Capital LLC increased its stake in shares of Medpace by 27.6% during the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock worth $45,000 after purchasing an additional 29 shares during the last quarter. HBK Sorce Advisory LLC grew its holdings in Medpace by 0.5% during the fourth quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company’s stock worth $1,789,000 after purchasing an additional 29 shares during the period. Assetmark Inc. increased its position in Medpace by 20.1% during the fourth quarter. Assetmark Inc. now owns 173 shares of the company’s stock worth $57,000 after buying an additional 29 shares during the last quarter. Proficio Capital Partners LLC raised its stake in Medpace by 4.1% in the fourth quarter. Proficio Capital Partners LLC now owns 730 shares of the company’s stock valued at $243,000 after buying an additional 29 shares during the period. Finally, Schulhoff & Co. Inc. lifted its position in shares of Medpace by 1.2% in the fourth quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company’s stock valued at $874,000 after buying an additional 30 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

Insider Buying and Selling at Medpace

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of the company’s stock in a transaction that occurred on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total transaction of $516,715.84. Following the completion of the sale, the director now owns 2,998 shares of the company’s stock, valued at approximately $904,856.36. This represents a 36.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 20.30% of the company’s stock.

Wall Street Analysts Forecast Growth

MEDP has been the topic of a number of recent analyst reports. William Blair reissued a “market perform” rating on shares of Medpace in a report on Tuesday, April 22nd. Leerink Partners began coverage on shares of Medpace in a report on Monday, March 24th. They issued a “market perform” rating and a $330.00 price objective on the stock. Leerink Partnrs upgraded shares of Medpace to a “hold” rating in a research note on Monday, March 24th. TD Cowen lowered shares of Medpace from a “buy” rating to a “hold” rating and decreased their price target for the company from $370.00 to $328.00 in a research note on Monday, April 14th. Finally, Mizuho lowered their price target on shares of Medpace from $400.00 to $355.00 and set an “outperform” rating on the stock in a report on Wednesday, April 9th. Eleven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $349.30.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $296.41 on Friday. The business’s 50 day simple moving average is $304.65 and its 200 day simple moving average is $327.86. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $459.77. The company has a market capitalization of $8.52 billion, a P/E ratio of 23.47, a P/E/G ratio of 3.81 and a beta of 1.55.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, April 21st. The company reported $3.67 EPS for the quarter, topping analysts’ consensus estimates of $3.06 by $0.61. The company had revenue of $558.57 million for the quarter, compared to analysts’ expectations of $528.38 million. Medpace had a return on equity of 51.48% and a net margin of 19.17%. During the same quarter last year, the business earned $3.20 earnings per share. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.